Wear N95 respirator mask, Omicron is a serious threat
Pfizer advances the development of a variant-specific vaccine for Omicron, available by March. Meanwhile, boost waning general COVID-19 vaccine to prevent serious outcomes.
- The speed of Omicron infection is unprecedented.
- “The overall threat from Omicron variant is likely to be very significant,” explains Dr. Michael Chan of the Hong Kong University who has led the first major study on the new variant.
- “Although two doses of the [Pfizer/BiooNTech] vaccine may still offer protection against severe disease caused by the Omicron strain, it’s clear from preliminary data that protection is improved with a third dose of our vaccine,” said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. “Ensuring as many people as possible are fully vaccinated with the first two dose series and a booster remains the best course of action to prevent the spread of COVID-19.” The company hopes to have an Omicron-specific vaccine in March 2022.
- Today there is a smattering of a contradictory indications, yet to be verified about the virility of the Omicron variant of SARS-CoV-2. Generally it is believed the variant’s severity is less than the delta variant. Small indications in Europe say otherwise. The data is scanty. A new, yet-to-be-verified study explains why Omicron disease is less severe for most healthy young patients.
- “Vulnerable patients are still at risk of severe outcomes as is the case with all viruses,” explained two medical experts FPMag interviewed for this article.
- A new study by the LKS Faculty of Medicine at The University of Hong Kong (HKUMed) shows that the Omicron infection in lungs is significantly lower than the ancestral SARS-CoV-2 virus.
- This research finding offers evidence that in general, lower disease severity may be prevalent in the healthy young population which is indeed the data from South Africa. Some indications in Europe signal an alarm. The new research report is currently under peer review for publication. Read on for the specifics …
1.) Omicron appears to evade antibodies from prior infections of the Beta and Delta variants of OCIVD-19, according to a very narrow study. Avoid this disease with a respirator mask, constant hand hygiene, and social distancing, says expert.
Read if you wish: Increased risk of SARS CoV 2 reinfection associated with Omicron
2) Another recently released scientific report points out that the Omicron variant of SARS-CoV-2 thrives in airway passages more than lungs.
“It is important to note that the severity of disease in humans is not determined only by virus replication but also by the host immune response to the infection, which may lead to dysregulation of the innate immune system, i.e.: ‘cytokine storm’,” said Dr. Michael Chan, Associate Professor, School of Public Health, HKUMed.
“It is also noted that, by infecting many more people, a very infectious virus may cause more severe disease and death even though the virus itself may be less pathogenic. Therefore, taken together with our recent studies showing that the Omicron variant can partially escape immunity from vaccines and past infection, the overall threat from Omicron variant is likely to be very significant,” said Dr. Chan.
Six-month ago vaccination will not offer much, if any at all, protection from infection by Omicron.
“I have believed this to have been a foregone conclusion because of the changing nature of the SARS-CoV-2 virus and the fact that we know from statistical evidence that immunity built from prior infection does NOT seem to last long, for any variant. The same would be true according to statistical evidence related to immunity afforded by long-ago vaccination,” said Dr. Fred Harris of the Civil Society Partners against COVID-19 tracking team in Singapore.
“That is also true of influenza, as we all know, the vaccination is good for a season, if that long. Hence, it is best to accept the evidence and get vaccinated fully and maintain the prescribed schedule. All available disease mitigation practices are also needed, like wearing a respirator mask, washing hands frequently and staying away from other people, until the SARS-CoV-2 virus has been denied all hosts and the pandemic is over,” the biostatistician and infectious disease researcher added.
“I agree with Dr. Harris,” commented Dr. Nassima al Amouri during a three-way virtual interview.
Vaccine ineffectiveness against Omicron is a concern. Basically, older Pfizer jabs do not work. Get boosted, says even Pfizer itself, but an Omicron-specific vaccine is in development.
“I frankly do not believe that people who were vaccinated fully by August of this year, have today, any significant measure of protection from infection from this new variant that has over 50 mutations, 30 of which relate to the spike protein which is how this thing evades immunity better than any previous variant of SASRS-CoV-2,” she added.
“Getting vaccinated is not enough to avoid infection from the Omicron mutated SARS virus. People must be instructed to wear one of N-95, KN-95, KF94, FFR-2 or any certified 95%+ effective respirator.
Pfizer is developing a vaccine that is relevant to specific SARS2 variant Omicron?
“Some people say it is likely very expensive to create new vaccines for Omicron. Another factor, the older vaccines and boosters in the millions would sit on a shelf, wasted and unsold, until expiration, if Pfizer introduced a more effective vaccine with Omicron specificity immediately. I do not know. Is it about economics? Not for patients, it isn’t. It’s about their health. Tell people to take command of their own health prospects and wear a respirator, and keep their hands clean,” added Dr. Nassima al Amouri. “Genuine respirator masks provide 95% efficacy against pathogens if worn properly.”
According to Pfizer and BioNTech on Wednesday, December 08, 2021:
- “Preliminary laboratory studies demonstrate that three doses of the Pfizer-BioNTech COVID-19 Vaccine neutralize the Omicron variant (B.1.1.529 lineage) while two doses show significantly reduced neutralization titers
- “Data indicate that a third dose of BNT162b2 increases the neutralizing antibody titers by 25-fold compared to two doses against the Omicron variant; titers after the booster dose are comparable to titers observed after two doses against the wild-type virus which are associated with high levels of protection
- “As 80% of epitopes in the spike protein recognized by CD8+ T cells are not affected by the mutations in the Omicron variant, two doses may still induce protection against severe disease
- “The companies continue to advance the development of a variant-specific vaccine for Omicron and expect to have it available by March in the event that an adaption is needed to further increase the level and duration of protection – with no change expected to the companies’ four billion dose capacity for 2022.” Citing a Pfizer-BioNTech release.
SARS2 Update 2022-06-27 04:00 GMT
- 254 Regions reported 548,232,792 cases
- 16,285,052 cases active
- 6,369,918 people reported killed by COVID-19
- 1.16% is current Case Fatality Rate (CFR)
- 525,577,822 survived COVID-19
Beta Technology Global Estimates
- 38.36% of all humans (3,031,727,339) have been infected
- 0.63% Global estimated inferred average Infection Fatality Rate (IFR)
(influenza is .1% or 6 per 100k (2019))
- 19,103,065 Total deaths (CSPaC.net estimated actual) including errors, and unreported likely-cause excess deaths such as people who never went to a hospital but had COVID-19 indications but never tested.
EPICENTER: USA (87,271,055)
- 145.01% of the USA may have been infected or even reinfected including reported + estimated unreported mild and estimated asymptomatic (482,608,934.15) human infections, some of which may not have been ill in their first course of the disease, but could have spread the disease.
- 1.19% is USA current Case Fatality Rate (CFR) &
- 0.27% is estimated inferred average Infection Fatality Rate (IFR)
- 1,303,044 estimated total COVID-19 deaths including unreported likely-cause excess deaths. According to projections of IHME, IHME calculation of excess deaths is slightly higher than what CSPaC is showing.
The RINJ Foundation helps women make the case for Vaccination of families
Please help cure the ignorance about immunization. AntiVaxxers are a serious threat to global health. Please share this information.
The RINJ Women help make the case for Vaccination of families
COVID-19 pandemic, endemic smallpox, polio, measles, pertussis & rubella are vaccine-preventable disease only if all humans maintain the resistance. Some disease are spreading because of never-established or waning immunity. That’s the case for universal immunization mandates and keeping the human race alive. Photo Credit: Melissa Hemingway / Feminine-Perspective Magazine